Doug Drysdale on Psychedelics & Breakthrough Therapies | Milken 2025

At the Milken Institute Global Conference, Worth Media’s Dan Costa sits down with Doug Drysdale, CEO of Cybin, for a compelling look into the evolving world of psychedelic-assisted mental health treatment—and how science is challenging decades of stigma and policy inertia.

Doug shares why psychedelic compounds offer a radically different approach to treating depression, how they’re designed to create long-lasting change in brain patterns, and where his company is in the process of gaining regulatory approval. With breakthrough therapy designation from the FDA, Cybin is at the forefront of a movement to reframe how we think about mental health interventions—and the role of nature-derived molecules.

In this wide-ranging discussion, Doug unpacks:

• Why psychedelics like psilocybin are showing results that last up to a year.
• How cultural stigma and outdated policy are slowly giving way to clinical progress.
• The real role of the FDA—and how collaborative their response has been.
• What drug development timelines look like, and when consumers might have access.
• Why psychedelic therapies may soon follow the path of cannabis, GHB, and other once-taboo treatments.